Antithrombotic agents for secondary ischemic stroke prevention in cancer patients with atrial fibrillation: A tertiary medical center retrospective study

Medicine 2026 Open access

Read full text
Authors: Ching-Wei Yu, Xin-Hong Lin, Kuan-Wen Chen, Chung‐Fu Hsu, Yu‐Cheng Lin, Hsin‐Yi Chi
DOI: 10.1097/md.0000000000047883
Cited by: 0
References: 29

Abstract

The coexistence of cancer and atrial fibrillation (AF) significantly exacerbates the risk of stroke recurrence and associated complications. The complex interplay between these conditions elevated the thromboembolic burden, bleeding risk, and all-cause mortality. However, the optimal antithrombotic strategy for secondary prevention in this population remains ill-defined. This study aims to compare the therapeutic outcomes of anticoagulant versus antiplatelet therapies in cancer patients with AF. This retrospective study identified ischemic stroke (IS) patients with both cancer and AF at a single medical center from January 2018 to June 2023. Patients receiving antithrombotic treatment for

Fields of Study & Subjects

Atrial Fibrillation Management and Outcomes Acute Ischemic Stroke Management Venous Thromboembolism Diagnosis and Management

Publication details

Journal / source
Medicine
Volume
105
Issue
10
Pages
e47883–e47883
Publication date
6 March 2026
Language
EN